-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $165

Benzinga·04/13/2026 16:45:53
Listen to the news
Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $150 to $165.